NDLI: Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation

Content Provider	JAMA Network
Author	Jessup, J. Milburn Stewart, Andrew Greene, Frederick L. Minsky, Bruce D.
Copyright Year	2005
Abstract	Context: A 1990 National Institutes of Health Consensus Conference recommended that patients with stage III colon cancer receive adjuvant chemotherapy because survival was improved in clinical trials in patients who received a 5-fluorouracil–based regimen. Objective: To determine whether adjuvant chemotherapy is used in the community as a standard of practice that improves outcome and whether it failed to benefit any specific sets of patients. Design, Setting, and Participants: Prospective data from 85 934 patients with stage III colon cancer from 560 hospital cancer registries were entered into the National Cancer Data Base between 1990 and 2002 and included standard clinical, pathological, and first course of treatment variables. Main Outcome Measures: Prevalence of adjuvant chemotherapy usage and 5-year survival in patients treated in US hospitals. Results: Adjuvant chemotherapy use increased from 39% in 1991 to 64% in 2002 but was lower in black, female, and elderly patients. It improved 5-year survival from almost 8% in 1991 to more than 16% in 1997 compared with surgery alone. Adjuvant chemotherapy increases survival in elderly patients as much as it does in younger patients. However, the benefit of adjuvant chemotherapy in blacks and those with high-grade cancers is not as great. Conclusions: Adjuvant chemotherapy use has increased from 1990 to 2002 for patients with stage III colon cancer with an associated increase in 5-year survival of 16%. The benefit of adjuvant chemotherapy seems to be lower in black patients and high-grade cancers. Women have the same benefit but are less often treated. Elderly patients have the same benefit as younger patients but are less frequently treated. New options for adjuvant therapy in 2004-2005 may further improve the outcome of patients with stage III colon cancer.
Ending Page	2711
Starting Page	2703
Page Count	9
File Format	PDF HTM / HTML
ISSN	00987484
DOI	10.1001/jama.294.21.2703
Issue Number	21
Journal	JAMA
Volume Number	294
Language	English
Publisher	American Medical Association
Publisher Date	2005-12-07
Access Restriction	Open
Subject Keyword	adjuvant chemotherapy colon cancer stage iii cancer operative surgical procedures fluorouracil adjuvant therapy
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.

Stage III Colon Cancers: Why Adjuvant Chemotherapy Is Not Offered to Elderly Patients

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis.

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Adjuvant Chemotherapy for Stage III Colon Cancer

For stage ii and iii colon cancer: a hellenic cooperative oncology group study.

Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer

Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation

Similar Documents

Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.

Stage III Colon Cancers: Why Adjuvant Chemotherapy Is Not Offered to Elderly Patients

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

Uracil-tegafur vs fluorouracil as postoperative adjuvant chemotherapy in Stage II and III colon cancer: A nationwide cohort study and meta-analysis.

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Adjuvant Chemotherapy for Stage III Colon Cancer

For stage ii and iii colon cancer: a hellenic cooperative oncology group study.

Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer

Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation